KPV: Research Overview

The short version

KPV is a very short peptide — just three amino acids, lysine-proline-valine — that happens to be the exact tail end (residues 11-13) of a much larger hormone called alpha-melanocyte-stimulating hormone (alpha-MSH). Alpha-MSH does several things in the body, including affecting skin pigment and calming inflammation. KPV keeps the anti-inflammatory part of that job without the pigment part.

Every study of KPV that exists is either a lab-dish (in vitro) study or an animal study — almost always mice with induced colitis (gut inflammation). As of this writing, there are no published human clinical trials of KPV at all. It is sold only as a research chemical. This page describes what the animal and cell-culture research shows, with the honest caveat that none of it has been tested in people.

What it is

KPV is the linear tripeptide L-lysyl-L-prolyl-L-valine (Lys-Pro-Val), molecular formula C16H30N4O4. It corresponds exactly to residues 11 through 13 — the C-terminal (tail) end — of alpha-melanocyte-stimulating hormone (alpha-MSH), a much larger hormone the body produces naturally. Researchers sometimes label KPV as 'alpha-MSH(11-13)' for this reason. Its category in the literature is a melanocortin-derived anti-inflammatory tripeptide: a small piece cut from a bigger 'melanocortin' hormone family, kept specifically because that fragment retains one of the parent hormone's jobs (calming inflammation) while dropping another (affecting melanin/pigment production). That makes KPV a useful teaching example of how researchers isolate one function out of a multi-function hormone by studying just the fragment responsible for it.

How it works

KPV is thought to dampen inflammation mainly by suppressing two well-known inflammatory signaling pathways inside cells — NF-kB and the MAP-kinase pathway — which reduces production of inflammatory signaling proteins called cytokines ^[15][17]. In the gut specifically, KPV has a distinctive way of getting into cells: it's small enough to be taken up directly by a transporter called PepT1 (a protein normally used to absorb the tail ends of digested proteins), and PepT1 is upregulated, turned up, in inflamed intestinal tissue, which may help concentrate KPV exactly where gut inflammation is worst ^[15]. Researchers describe this PepT1 route as a reason KPV keeps drawing interest specifically for inflammatory bowel disease, even though — as with everything on this page — the evidence for it is preclinical (lab and animal), not clinical.

What the research shows

Targeted nanoparticle delivery (2024). A PepT1-targeted nanodrug combining KPV with the immunosuppressant FK506 improved both acute and chronic colitis in mice, restoring gut tight-junction proteins, which keep the intestinal lining sealed, and lowering inflammatory cytokines more than either drug alone ^[13].

Oral nanoparticle delivery. An earlier study built KPV into hyaluronic-acid nanoparticles inside a hydrogel, designed to survive digestion and release KPV directly in inflamed colon tissue in mice; this targeted delivery reduced mucosal damage and a key inflammatory cytokine (TNF-alpha) more effectively than non-targeted KPV ^[14].

The foundational PepT1 mechanism paper. The first detailed study of how KPV enters cells found it is transported via PepT1 into human intestinal cells, and that nanomolar concentrations of KPV reduced NF-kB and MAP-kinase inflammatory signaling in both intestinal and immune cells in a dish; orally administered KPV also reduced colitis severity in two different mouse models ^[15].

Colitis in mice, including a genetically modified strain. KPV reduced colonic inflammation in mice with induced colitis, with earlier recovery, less inflammatory tissue damage, and — notably — the effect held up even in mice genetically missing the MC1R receptor, suggesting KPV's anti-inflammatory action doesn't depend on that particular receptor ^[16].

A broad review of the melanocortin tripeptide family. A comprehensive review describes KPV and related tripeptides as protective across a wide range of inflammatory animal models — fever, dermatitis, arthritis, gut, brain, and airway inflammation among them — while specifically noting KPV lacks the pigment-affecting action of full alpha-MSH ^[17].

Reported effects, cautions & safety

KPV has no published real-world user reports and no dedicated safety-caution literature to draw on — unlike the other three peptides on this site, it hasn't built up an online community of research-use reports, and its entire evidence base is lab and animal work. That absence is itself the most important caution: with no published human trials of any kind, there is no established human dose, no documented human side-effect profile, and no way to verify what a given research-chemical product actually contains. Marketing claims for KPV around gut health, skin, or general anti-inflammatory use outrun the underlying evidence, which remains mechanistic and preclinical rather than clinical ^[17].

Where KPV fits in research peptide fundamentals

KPV is this site's clearest illustration of the gap between mechanism and human evidence: a well-characterized, three-amino-acid hormone fragment with a specific and testable cellular pathway, PepT1 uptake and NF-kB suppression, and zero published human trials. Compare that to semaglutide, an engineered peptide with over a decade of large human trials behind it, or GHK-Cu, whose topical form does have real human data. See the full comparison for how the four line up on evidence maturity.